Collegium Pharmaceutical, Inc. (COLL)

Market Cap	1.40B +42.0%
Revenue (ttm)	780.57M +23.6%
Net Income	62.87M -9.1%
EPS	1.73 -7.0%
Shares Out	31.61M
PE Ratio	25.56
Forward PE	5.61
Dividend	n/a
Ex-Dividend Date	n/a

Volume	568,468
Open	41.75
Previous Close	45.75
Day's Range	41.00 - 45.18
52-Week Range	23.23 - 50.79
Beta	0.65
Analysts	Strong Buy
Price Target	50.83 (+14.95%)
Earnings Date	Feb 26, 2026

About COLL

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company’s portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxyco...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 7, 2015
• Employees: 357
• Stock Exchange: NASDAQ
• Ticker Symbol: COLL
• Website: https://www.collegiumpharma.com

Financial Performance

In 2025, Collegium Pharmaceutical's revenue was $780.57 million, an increase of 23.62% compared to the previous year's $631.45 million. Earnings were $62.87 million, a decrease of -9.13%.

Analyst Summary

According to 6 analysts, the average rating for COLL stock is "Strong Buy." The 12-month stock price target is $50.83, which is an increase of 14.95% from the latest price.

Price Target

$50.83

(14.95% upside)

Analyst Consensus: Strong Buy